Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 23.
Online ahead of print.

Interim Guidelines on Antiviral Therapy for COVID-19

Affiliations
  • PMID: 32342676
Free article
Review

Interim Guidelines on Antiviral Therapy for COVID-19

Sun Bean Kim et al. Infect Chemother. .
Free article

Abstract

Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.

Keywords: Antiviral; COVID-19; SARS-CoV-2; Treatment.

Comment in

Similar articles

See all similar articles
Feedback